Special Issue

Recent Advances in Therapeutic Antibody

Message from the Guest Editor

The development of therapeutic monoclonal antibodies (mAbs) has remarkably evolved over the past 10 years, and healthcare will still be largely driven by these biologics for the foreseeable decades. Indeed, the number of full-length mAbs, including biosimilars, and derivatives such as Fc-fusion proteins or drug-conjugates, are now part of the therapeutic arsenal. In particular, the arrival of antibodies modulating the immune checkpoints has brought a significant improvement in the field of oncology, while successes in the field of inflammation and autoimmunity have also been confirmed. However, other medical areas covered by the use of mAbs have also expanded, resulting in many new indications. With regard to new formats, multi-specific and novel shapes, such as nanobodies, are mostly in earlier stages of development, but the way forward is promising and exciting. This Special Issue will be composed of original research articles and reviews. We are looking forward to receiving your contributions. Let us see what is really recent in the therapeutic antibodies area.

Guest Editor

Dr. Isabelle Turbica

Inserm, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92290 Châtenay-Malabry, France

Deadline for manuscript submissions

closed (30 September 2023)

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed

mdpi.com/journal/
pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).